Table 1.
CGRP-targeted mAbs and Gepants
| Name | Target | Route | T1/2 | Tmax | Dose | Frequency |
|---|---|---|---|---|---|---|
| Erenumab (AMG334) | Receptor | SC | 28 days | 6 days | 70mg | QM |
| 140mg | QM | |||||
| Fremanezumab (TEV48125) | Ligand | SC | 32 days | 5 days | 225mg | QM |
| 675mg | QLT | |||||
| Galcanezumab (LY2951742) | Ligand | SC | 27 days | 5 days | 120mg | QM |
| Eptinezumab (ALD403) | Ligand | IV | 27 days | 1–3 hours | 100mg | QLT |
| 300mg | QLT | |||||
| Ubrogepant (MK-1602) | Receptor | PO | 5–7 hours | 1.5 hours | 50mg | PRN |
| 100mg | ||||||
| Rimegepant (BMS-927711) | Receptor | PO | 11 hours | 1.5 hours | 75mg | PRN |
| QOD | ||||||
| Atogepant (MK-8031) | Receptor | PO | 11 hours | 2 hours | 10mg | QD |
| 30mg | ||||||
| 60mg |
Notes: All except ubrogepant and rimegepant were preventive medications.
Abbreviations: T1/2, plasma concentration half-life; Tmax, time to maximal plasma concentration; IV, intravenous; SC, subcutaneous; QLT, quarterly; QM, monthly; PO: QoD, every other day; QD, daily; PRN, as needed.